Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.67 - $24.46
Previous CloseN/A
Volume2.33M
Average Volume (3M)17.67M
Market Cap
$43.65B
Enterprise Value$49.18B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$8.72B
Price to Earnings (P/E)42.3
Beta0.40
Next Earnings
May 08, 2025EPS Estimate
0.23Next Dividend Ex-Date
May 14, 2025Dividend Yield3.55%
Share Statistics
EPS (TTM)0.54
Shares Outstanding1,918,691,200
10 Day Avg. Volume20,191,584
30 Day Avg. Volume17,665,189
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.88
Price to Cash Flow (P/CF)14.10
P/FCF Ratio12.40
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.49
Enterprise Value/Ebitda15.53
Forecast
1Y Price Target
$24.15Price Target Upside6.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementKVUE’s ‘Our Vue Forward’ program is on track to generate an annualized run rate of $350mn in savings by FY26, which should continue to fuel its marketing and brand support.
InnovationThe company plans a 40% growth in innovation across all divisions in 2025, with bolder and faster new launches and increased investments in influencers and digital marketing.
Investment StrategyA key tenet in the KVUE investment case is predicated on turning around the firm’s Skin Health & Beauty segment through greater focus and higher reinvestment funded by supply-chain savings that have come ahead of schedule.
Bears Say
Market ConditionsNear-term challenges exist with disruption at its distribution network within APAC, especially in China, and a weaker start to the cough, cold, & flu season in the US and China.
Sales ForecastExpectations for Q1 volumes at KVUE’s skin health & beauty segment are tempered given recent weakness in Nielsen data.
Sales PerformanceSkin Health & Beauty sales fell 2% in 2024 despite a 20% hike in marketing spend and are down 4% at U.S. retail through mid-March 2025.
---
Ownership Overview
1.18% Insiders
36.18% Mutual Funds
0.56% Other Institutional Investors
35.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $17.67 and its highest was $24.46 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $43.65B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Feb 06, 2025. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.257 by $0.003.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.812 which represents an annual dividend yield of 3.55%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.23.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,918,691,200 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.26 in its last earnings report, beating expectations of $0.257. Following the earnings report the stock price went down -4.576%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
---
Kenvue, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.15 (6.15% Upside)
$24.15 (6.15% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 77%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 19.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $393.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.62%
12-Months-Change
Fundamentals
Return on Equity
9.87%
Trailing 12-Months
Asset Growth
-8.08%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
---
KVUE Company Deck
---
KVUE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Kenvue's efforts in improving gross margins, investing in brand growth, and achieving share gains in the self-care segment. However, these positive developments were tempered by underperformance in organic sales growth, distribution challenges in China, and a decline in the pediatric pain franchise due to a weak flu season. The outlook for 2025 is cautiously optimistic, with expected improvements in operational efficiency and strategic investments, but also acknowledges external economic challenges.Read More>---
KVUE Revenue Breakdown
42.23% Self Care
30.33% Essential Health
27.43% Skin Health and Beauty
---
KVUE Stock 12 Month Forecast
Average Price Target
$24.15
▲(6.15% Upside)
Technical Analysis
Best Analysts Covering KVUE
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+11.95%
reiterated a buy rating 2 months ago
Copying Susan Anderson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.95% per trade.
---